Terumo Corporation
TSE:4543 Stock Report
Terumo Future Growth
Future criteria checks 3/6 Terumo is forecast to grow earnings and revenue by 11.8% and 5.8% per annum respectively. EPS is expected to grow by 12.1% per annum. Return on equity is forecast to be 10.8% in 3 years.
Key information
11.8%
Earnings growth rate
Medical Equipment earnings growth 12.5% Revenue growth rate 5.8% Future return on equity 10.8% Analyst coverage Good
Last updated 11 Nov 2024
Recent future growth updates
Show all updates
Terumo Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now Nov 11
Returns At Terumo (TSE:4543) Appear To Be Weighed Down Nov 08
Second quarter 2025 earnings: EPS misses analyst expectations Nov 08
Terumo Corporation to Report Q2, 2025 Results on Nov 07, 2024 Sep 25
Upcoming dividend of JP¥13.00 per share Sep 20
Estimating The Fair Value Of Terumo Corporation (TSE:4543) Sep 16 Terumo Corporation (TSE:4543) announces an Equity Buyback for 15,000,000 shares, representing 1.01% for ¥30,000 million. Aug 30
Terumo Corporation Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next Aug 11
First quarter 2025 earnings: EPS and revenues exceed analyst expectations Aug 09
Investor sentiment deteriorates as stock falls 22% Aug 05
Now 22% undervalued after recent price drop Aug 02
Investors Still Waiting For A Pull Back In Terumo Corporation (TSE:4543) Jul 21
Final dividend of JP¥13.00 announced Jul 11
Full year 2024 earnings: EPS in line with analyst expectations despite revenue beat Jul 05
Terumo (TSE:4543) Has A Pretty Healthy Balance Sheet Jul 05
Less than half of directors are independent Jul 02
Return Trends At Terumo (TSE:4543) Aren't Appealing Jun 20
Now 20% overvalued Jun 07
Terumo Corporation to Report Q1, 2025 Results on Aug 08, 2024 Jun 02
Terumo Cardiovascular Announces 510(K) Clearance for the CDI Oneview™? Monitoring System May 29
Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind May 16
Price target increased by 10% to JP¥3,255 May 15
Calculating The Fair Value Of Terumo Corporation (TSE:4543) May 12
Investors Still Waiting For A Pull Back In Terumo Corporation (TSE:4543) Apr 12
Consensus EPS estimates increase by 11% Apr 06
Price target increased by 7.4% to JP¥3,136 Mar 30
Terumo (TSE:4543) Has Announced A Dividend Of ¥22.00 Mar 27
New minor risk - Dividend sustainability Mar 27
Upcoming dividend of JP¥22.00 per share Mar 21
Terumo Corporation to Report Fiscal Year 2024 Results on May 14, 2024 Mar 17
Is Terumo (TSE:4543) Using Too Much Debt? Feb 29
Price target increased by 7.3% to JP¥5,548 Feb 27
Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024 Feb 09
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Feb 08 Terumo Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024 Terumo Corporation, Annual General Meeting, Jun 26, 2024
Terumo Corporation to Report Q3, 2024 Results on Feb 07, 2024 Dec 03
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Nov 16
Terumo Corporation to Report Q2, 2024 Results on Nov 14, 2023 Oct 01
Upcoming dividend of JP¥22.00 per share at 1.1% yield Sep 21
Terumo Corporation (TSE:4543) announces an Equity Buyback for 5,000,000 shares, representing 0.67% for ¥20,000 million. Aug 10
First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 10
Terumo Corporation to Report Q1, 2024 Results on Aug 09, 2023 Jun 21 Terumo Corporation Announces Fiscal Year-End Dividend for the Fiscal Year Ended March 31, 2023, Payable on June 28, 2023; Provides Second Quarter-End Dividend Guidance for the Fiscal Year Ending March 31, 2024 and Provides Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024
Full year 2023 earnings: EPS misses analyst expectations May 17
Terumo Corporation, Annual General Meeting, Jun 27, 2023 May 16
Upcoming dividend of JP¥21.00 per share at 1.2% yield Mar 23
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Feb 10 Terumo Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023
Less than half of directors are independent Nov 16
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 12 Terumo Corporation Announces Dividend for the Second Quarter End of Fiscal Year 2023, Commences Dividend Payments on December 5, 2022; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023
Terumo Corporation to Report Q3, 2023 Results on Nov 10, 2023 Nov 10
Terumo Corporation to Report Q2, 2023 Results on Nov 10, 2022 Sep 28
Upcoming dividend of JP¥18.00 per share Sep 22
Mitsui DM Sugar Holdings Co.,Ltd. (TSE:2109) agreed to acquire Enteral formula business of Terumo Corporation from Terumo Corporation (TSE:4543). Sep 09
NUTRI Co.,Ltd. entered into an agreement to acquire Nutritional food and related product assets of Terumo Corporation. Sep 08
First quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 10 Terumo Corporation Provides Dividend Guidance for the Second Quarter of Year Ending March 31, 2023
Less than half of directors are independent Jul 05
Terumo Announces Change in Indication for Dexcom G6 CGM System in Japan May 16
Full year 2022 earnings: EPS misses analyst expectations May 14 Terumo Corporation (TSE:4543) announces an Equity Buyback for 15,000,000 shares, representing 1.98% for ¥50,000 million.
Less than half of directors are independent Apr 27
Terumo Corporation to Report Fiscal Year 2022 Results on May 12, 2022 Apr 08
Upcoming dividend of JP¥16.00 per share Mar 23
Third quarter 2022 earnings: EPS misses analyst expectations Feb 10
Terumo Corporation, Annual General Meeting, Jun 22, 2022 Feb 10 Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2022
Second quarter 2022 earnings released: EPS JP¥29.22 (vs JP¥23.63 in 2Q 2021) Nov 05
Upcoming dividend of JP¥15.00 per share Sep 22
First quarter 2022 earnings released: EPS JP¥36.90 (vs JP¥18.57 in 1Q 2021) Aug 05
Full year 2021 earnings released: EPS JP¥102 (vs JP¥114 in FY 2020) Jun 27
Full year 2021 earnings released: EPS JP¥102 (vs JP¥114 in FY 2020) May 14 Terumo Corporation Provides Dividend Guidance for the Year Ending March 2022
Upcoming dividend of JP¥14.00 per share Mar 23
New 90-day low: JP¥3,951 Feb 26
Terumo Corporation (TSE:4543) signed definitive agreement to acquire All Assets from Health Outcomes Sciences, Inc. Feb 25
Terumo Corporation Announces Clinical Study in Japan for Product Using Terumo's Automated Injection Device Developed in Collaboration with Kyowa Kirin Co., Ltd Feb 08
Earnings and Revenue Growth Forecasts TSE:4543 - Analysts future estimates and past financials data (JPY Millions) Date Revenue Earnings Free Cash Flow Cash from Op Avg. No. Analysts 3/31/2027 1,169,772 169,157 123,813 221,955 14 3/31/2026 1,090,492 150,163 108,685 205,688 15 3/31/2025 1,020,810 130,839 96,293 180,438 11 9/30/2024 986,674 119,486 114,170 193,649 N/A 6/30/2024 964,805 117,716 92,134 170,598 N/A 3/31/2024 921,863 106,374 67,556 146,330 N/A 12/31/2023 885,167 99,042 60,490 133,870 N/A 9/30/2023 860,767 99,096 35,316 110,769 N/A 6/30/2023 838,121 89,476 30,037 105,606 N/A 3/31/2023 820,209 89,325 45,363 117,536 N/A 12/31/2022 797,814 87,297 47,491 117,976 N/A 9/30/2022 761,982 79,146 65,356 135,078 N/A 6/30/2022 728,927 83,316 65,052 134,924 N/A 3/31/2022 703,303 88,813 67,362 141,467 N/A 12/31/2021 688,696 90,363 69,610 146,371 N/A 9/30/2021 675,183 95,414 69,307 146,611 N/A 6/30/2021 654,260 91,161 53,415 133,980 N/A 3/31/2021 613,842 77,268 38,573 121,485 N/A 12/31/2020 607,381 76,919 27,594 117,626 N/A 9/30/2020 604,915 71,342 20,121 109,392 N/A 6/30/2020 607,669 76,422 28,116 115,667 N/A 3/31/2020 628,897 85,211 33,995 117,479 N/A 12/31/2019 626,016 89,868 35,756 109,420 N/A 9/30/2019 621,762 90,727 34,047 104,160 N/A 6/30/2019 608,987 84,170 38,464 100,340 N/A 3/31/2019 599,481 79,470 39,207 93,571 N/A 12/31/2018 594,429 84,305 N/A N/A N/A 9/30/2018 588,162 92,782 61,609 106,706 N/A 6/30/2018 591,483 93,095 N/A N/A N/A 3/31/2018 587,775 91,295 N/A 114,562 N/A 12/31/2017 576,725 85,888 N/A N/A N/A 9/30/2017 553,664 66,769 N/A 87,995 N/A 6/30/2017 528,957 60,406 N/A N/A N/A 3/31/2017 514,164 54,225 N/A 80,862 N/A 12/31/2016 503,429 39,014 N/A N/A N/A 9/30/2016 510,969 44,087 N/A 85,463 N/A 6/30/2016 520,885 46,282 N/A N/A N/A 3/31/2016 525,026 50,676 N/A 80,303 N/A 12/31/2015 522,296 48,528 N/A N/A N/A 9/30/2015 515,364 43,603 N/A 80,102 N/A 6/30/2015 503,221 44,580 N/A N/A N/A 3/31/2015 489,506 38,470 N/A 73,110 N/A 12/31/2014 485,301 30,626 N/A N/A N/A 9/30/2014 474,640 36,517 N/A 86,298 N/A 6/30/2014 471,214 33,534 N/A N/A N/A 3/31/2014 467,360 34,096 N/A 96,260 N/A 12/31/2013 451,805 59,203 N/A N/A N/A
Show more
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4543's forecast earnings growth (11.8% per year) is above the savings rate (0.3%).
Earnings vs Market: 4543's earnings (11.8% per year) are forecast to grow faster than the JP market (9.1% per year).
High Growth Earnings: 4543's earnings are forecast to grow, but not significantly .
Revenue vs Market: 4543's revenue (5.8% per year) is forecast to grow faster than the JP market (4.2% per year).
High Growth Revenue: 4543's revenue (5.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4543's Return on Equity is forecast to be low in 3 years time (10.8%).
Discover growth companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
